Showing 1591-1600 of 5771 results for "".
- Azura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunctionhttps://modernod.com/news/azura-ophthalmics-announces-positive-results-from-phase-2b-clinical-trial-of-azr-md-001-in-meibomian-gland-dysfunction/2481247/Azura Ophthalmics announced positive 3-month efficacy and safety results from its phase 2b study of AZR-MD-001 0.5% in Meibomian Gland Dysfunction (MGD). The trial met its co-primary endpoints of improvements in Meibomian Glands Yielding Liquid Secretion (MGYLS; number of open glands) and Oc
- Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)https://modernod.com/news/viridian-announces-positive-data-from-ongoing-phase-12-trial-evaluating-vrdn-001-in-patients-with-thyroid-eye-disease-ted/2481240/Viridian Therapeutics announced positive topline clinical data from the first two cohorts in its ongoing phase 1/2 clinical trial of VRDN-001, an anti-IGF-1R antibody, in patients with active thyroid eye disease (TED). TED is a rare autoimmune disease in which the body’s own immune sys
- Luminopia Announces Oversubscribed Seed Extension Financing Round to Fund Amblyopia Treatmenthttps://modernod.com/news/luminopia-announces-oversubscribed-seed-extension-financing-round-to-fund-amblyopia-treatment/2481237/Luminopia, a prescription digital therapeutics company developing a new class of treatments for neuro-visual disorders, announced an oversubscribed $5.7M seed extension financing round. The company will be using the funding for a staged rollout of its lead product for amblyopia to pediatric
- Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX in Wet AMD Patientshttps://modernod.com/news/clearside-biomedical-announces-positive-results-in-safety-durability-and-biologic-effect-in-oasis-phase-12a-clinical-trial-of-suprachoroidal-cls-ax-in-wet-amd-patients/2481234/Clearside Biomedical announced positive results from its OASIS phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector in wet age-related macular degeneration (AMD) patients. Trial results include f
- Aviceda Announces Additional Members to its Clinical Advisory Board to Support its Clinical Development Strategy in Ophthalmologyhttps://modernod.com/news/aviceda-announces-additional-members-to-its-clinical-advisory-board-to-support-its-clinical-development-strategy-in-ophthalmology/2481232/Aviceda Therapeutics, a clinical-stage biotech company focused on developing the next generation of immuno-modulators, announced the addition of ophthalmic key opinion leaders to its clinical advisory board. The new additional Aviceda Clinical Advisory Board members are:
- MediPrint Ophthalmics Announces It Has Initiated Its SIGHT-2 Phase 2b Clinical Study for Its Lead Assethttps://modernod.com/news/mediprint-ophthalmics-announces-it-has-initiated-its-sight-2-phase-2b-clinical-study-for-its-lead-asset/2481231/MediPrint Ophthalmics announced it has initiated its SIGHT-2 dose-finding phase 2b study for its proprietary drug-eluting contact lens for glaucoma. This is the second study in its SIGHT (Sustained Innovative Glaucoma and ocular Hypertension Treatment) clinical program aimed at treating
- Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI Surgical System in Pseudophakic Glaucoma Patientshttps://modernod.com/news/sight-sciences-announces-publication-of-clinical-data-demonstrating-standalone-effectiveness-of-the-omni-surgical-system-in-pseudophakic-glaucoma-patients-with-uncontrolled-pressure-following-a-previous-combination-cataract-stent-procedure/2481221/Sight Sciences announced International Ophthalmology has published clinical data demonstrating the safety and effectiveness of the OMNI Surgical System as a minimally invasive, implant-free standalone (not in combination with cataract surgery) glaucoma procedure for pseudophaki
- Neurotech Pharmaceuticals Announces Positive Phase 3 Topline Results for NT-501 Implant in Macular Telangiectasia Type 2https://modernod.com/news/neurotech-pharmaceuticals-announces-positive-phase-3-topline-results-for-nt-501-implant-in-macular-telangiectasia-type-2/2481217/Neurotech Pharmaceuticals announced positive topline results in two replicative phase 3 clinical trials with their investigational encapsulated cell therapy (ECT) for the treatment of Macular telangiectasia type 2 (MacTel), an orphan, slowly progressive degenerative disease of the macula that res
- Ocuphire Announces Peer-Reviewed Publication for Nyxol and Strategic Partnership with ASOAhttps://modernod.com/news/ocuphire-announces-peer-reviewed-publication-for-nyxol-and-strategic-partnership-with-asoa/2481215/Ocuphire Pharma announced that the positive results in night vision disturbances (NVD) patients from its earlier and first phase 2 study evaluating the safety and efficacy of phentolamine mesylate eye drops (Nyxol) have been peer-reviewed and published in BMC Ophthalmology. <
- Unity Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with DMEhttps://modernod.com/news/unity-biotechnology-announces-positive-24-week-data-from-phase-2-behold-study-of-ubx1325-in-patients-with-dme/2481214/Unity Biotechnology announced that the key safety and efficacy endpoints were met at 24 weeks in the phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema (DME). The company intends to initiate a pivotal study in DME in the second half of 2023. At 24 weeks af